160 related articles for article (PubMed ID: 29618692)
21. [Comparison of low-dose thalidomide and prednisone combined with or without danazol for the treatment of primary myelofibrosis-associated anemia].
Xu J; Xu Z; Qin T; Li B; Fang L; Zhang H; Hu N; Pan L; Qu S; Zhang Y; Xiao Z
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):698-702. PubMed ID: 25152115
[TBL] [Abstract][Full Text] [Related]
22. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
Merup M; Kutti J; Birgergård G; Mauritzson N; Björkholm M; Markevärn B; Maim C; Westin J; Palmblad J;
Med Oncol; 2002; 19(2):79-86. PubMed ID: 12180484
[TBL] [Abstract][Full Text] [Related]
23. Struggling with myelofibrosis-associated anemia.
Guglielmelli P; Vannucchi AM
Leuk Res; 2013 Nov; 37(11):1429-31. PubMed ID: 24011697
[No Abstract] [Full Text] [Related]
24. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results.
Cervantes F; Isola IM; Alvarez-Larrán A; Hernández-Boluda JC; Correa JG; Pereira A
Ann Hematol; 2015 Nov; 94(11):1791-6. PubMed ID: 26122869
[TBL] [Abstract][Full Text] [Related]
25. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
26. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
27. Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib.
Andrei M; Sindhu H; Wang JC
Leuk Lymphoma; 2015 Feb; 56(2):524-6. PubMed ID: 24893800
[No Abstract] [Full Text] [Related]
28. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
29. Immunomodulatory agents in myelofibrosis.
Tabarroki A; Tiu RV
Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
[TBL] [Abstract][Full Text] [Related]
30. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Chifotides HT; Bose P; Verstovsek S
J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
[TBL] [Abstract][Full Text] [Related]
31. Thalidomide for the treatment of idiopathic myelofibrosis.
Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
[TBL] [Abstract][Full Text] [Related]
32. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
Colagrande M; Di Ianni M; Coletti G; Peris K; Fargnoli MC; Moretti L; Lapecorella M; Tabilio A
Int J Hematol; 2009 Jan; 89(1):76-79. PubMed ID: 19052692
[TBL] [Abstract][Full Text] [Related]
33. Thalidomide in agnogenic and secondary myelofibrosis.
Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
[TBL] [Abstract][Full Text] [Related]
34. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
[TBL] [Abstract][Full Text] [Related]
35. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
[TBL] [Abstract][Full Text] [Related]
36. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
37. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
Berrebi A; Feldberg E; Spivak I; Shvidel L
Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
[TBL] [Abstract][Full Text] [Related]
38. Pomalidomide.
Engelhardt M; Wäsch R; Reinhardt H; Kleber M
Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
[TBL] [Abstract][Full Text] [Related]
39. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
[No Abstract] [Full Text] [Related]
40. Loss of transfusion dependency following deferasirox treatment of iron overload in a woman with myelofibrosis and spherocytosis - a case report.
Tesch H; Ihling C
Onkologie; 2013; 36(4):205-8. PubMed ID: 23548970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
